Lyell Immunopharma, Inc.

US$14.86As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:LYELHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (43.77%)
Div yield —
ROE (97.79%)
Biotechnology
Beta (5Y) (0.09)
PE TTM —
TSR TTM (10.80%)
Mkt cap US$365.3M
ROIC (40.63%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$15
4.05%
(50.14%)
Hold 0|3|9|1|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.19
0.20
0.19
0.21
9.11%
8.19%
2.56%
7.13%
Revenue$M
26.77
27.36
26.94
26.94
0.19%
4.25%
2.32%
2.43%
Peers (US$365.3M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
1.059
—
—
EBIT/Intx
3.681
1.153
1.008
Own earn%
55.85
(49.65)
(50.69)
Sh yield%
24.43
27.39
29.82
Owners
Insiders/Inst%
9.17
40.51
Short interest%
3.52
SBC / revenue%
2.50
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
1
Op margin range%
17–25
$1 testx
—
Incr. ROIC%
2